

Fig. 1a VEGFR-3+ cells (%) in blood of 5-FU treated FVB mice (n=4)






Fig. 1b VEGFR-3+ (%) cells in bone marrow after 5-FU treatment of FVB mice




BEST AVAILABLE COPY

**Fig. 2a WBC counts of blood in 5-FU and
ad novirus treated FVB mice**



BEST AVAILABLE COPY

**Fig. 2b WBC counts of blood in 5-FU and
adenovirus treated NMRI mice**



**Fig. 2c WBC counts of blood after 5-FU
and adenoviral treatment on day 10 in
FVB mice**





Fig. 3a VEGFR-1+ cells (%) of WBCs



BEST AVAILABLE COPY

Fig. 3b VEGFR-2+ cells (%) of WBCs






Fig. 3c VEGFR-3+ cells (%) of WBCs




BEST AVAILABLE COPY

Fig. 3d CD34+ cells (%) of WBCs



BEST AVAILABLE COPY

FIG. 4



BEST AVAILABLE COPY

FIG. 5




FIG. 6a





FIG. 6b



microvessel outgrowth




FIG. 7a

Fibroblast proliferation and migration




FIG. 7b

FIG. 8a




FIG. 8b




FIG. 8c

